Doucet Alain, Overall Christopher M
University of British Columbia, Centre for Blood Research, 4.401 Life Sciences Institute, 2350 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3.
Mol Aspects Med. 2008 Oct;29(5):339-58. doi: 10.1016/j.mam.2008.04.003. Epub 2008 May 1.
Proteases irreversibly modify proteins by cleaving their amide bonds and are implicated in virtually every important biological process such as immunity, development and tissue repair. Accordingly, it is easy to see that deregulated proteolysis is a pathognomic feature of many diseases. Most of the current information available on proteases was acquired using in vitro methods, which reveals molecular structure, enzyme kinetics and active-site specificity. However, considerably less is known about the relevant biological functions and combined roles of proteases in moulding the proteome. Although models using genetically modified animals are powerful, they are slow to develop, they can be difficult to interpret, and while useful, they remain only models of human disease. Therefore, to understand how proteases accomplish their tasks in organisms and how they participate in pathology, we need to elucidate the protease degradome-the repertoire of proteases expressed by a cell, a tissue or an organism at a particular time-their expression level, activation state, their biological substrates, also known as the substrate degradome-the repertoire of substrates for each protease-and the effect of the activity of each protease on the pathways of the system under study. Achieving this goal is challenging because several proteases might cleave the same protein, and proteases also form pathways and interact to form the protease web [Overall, C.M., Kleifeld, O., 2006. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6 (3), 227-239]. Hence, the net proteolytic potential of the degradome at a particular time on a substrate and pathway must also be understood. Proteomics offers one of the few routes to the understanding of proteolysis in complex in vivo systems and especially in man where genetic manipulations are impossible. The aim of this chapter is to review methods and tools that allow researchers to study protease biological functions using proteomics and mass spectrometry. We describe methods to assess protease expression at the messenger RNA level using DNA microarrays and at the protein level using mass spectrometry-based proteomics. We also review methods to reveal and quantify the activity state of proteases and to identify their biological substrates. The information acquired using these high throughput, high content techniques can then be interpreted with different bioinformatics approaches to reveal the effects of proteolysis on the system under study. Systems biology of the protease web-degradomics in the broadest sense-promises to reveal the functions of proteases in homeostasis and in disease states. This will indicate which proteases participate in defined pathologies and will help targeting specific proteases for disease treatments.
蛋白酶通过切割蛋白质的酰胺键对其进行不可逆修饰,几乎涉及免疫、发育和组织修复等每一个重要的生物学过程。因此,不难看出蛋白水解失调是许多疾病的病理特征。目前关于蛋白酶的大多数现有信息是通过体外方法获得的,这些方法揭示了分子结构、酶动力学和活性位点特异性。然而,对于蛋白酶在塑造蛋白质组中的相关生物学功能和联合作用,我们所知甚少。虽然使用转基因动物的模型很强大,但它们开发缓慢,可能难以解释,而且虽然有用,但它们仍然只是人类疾病的模型。因此,为了了解蛋白酶如何在生物体中完成其任务以及它们如何参与病理学,我们需要阐明蛋白酶降解组——细胞、组织或生物体在特定时间表达的蛋白酶库——它们的表达水平、激活状态、它们的生物学底物,也称为底物降解组——每种蛋白酶的底物库——以及每种蛋白酶的活性对所研究系统途径的影响。实现这一目标具有挑战性,因为几种蛋白酶可能切割同一蛋白质,而且蛋白酶还形成途径并相互作用形成蛋白酶网络[奥弗尔,C.M.,克莱费尔德,O.,2006年。肿瘤微环境——观点:验证基质金属蛋白酶作为癌症治疗的药物靶点和抗靶点。《自然综述:癌症》6(3),227 - 239]。因此,还必须了解降解组在特定时间对底物和途径的净蛋白水解潜力。蛋白质组学提供了为数不多的途径之一,用于理解复杂体内系统中的蛋白水解,尤其是在无法进行基因操作的人类中。本章的目的是综述使研究人员能够利用蛋白质组学和质谱研究蛋白酶生物学功能的方法和工具。我们描述了使用DNA微阵列在信使RNA水平评估蛋白酶表达以及使用基于质谱的蛋白质组学在蛋白质水平评估蛋白酶表达的方法。我们还综述了揭示和量化蛋白酶活性状态以及鉴定其生物学底物的方法。然后,可以使用不同的生物信息学方法解释通过这些高通量、高内涵技术获得的信息,以揭示蛋白水解对所研究系统的影响。蛋白酶网络的系统生物学——最广义的降解组学——有望揭示蛋白酶在体内平衡和疾病状态中的功能。这将表明哪些蛋白酶参与特定的病理学过程,并有助于针对特定蛋白酶进行疾病治疗。